Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esomeprazole + amoxicillin + clarithromycin + bismuth potassium citrate
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A bismuth-containing quadruple therapy regimen used for the eradication of *Helicobacter pylori* (*H. pylori*) infection. This combination includes esomeprazole (a proton pump inhibitor), amoxicillin and clarithromycin (antibiotics), and bismuth potassium citrate. The regimen is typically administered for 7-14 days and has been studied as a treatment for *H. pylori* infection.
- Other names
- bismuth-containing quadruple therapyTPB therapy
02
Targets
Bacterial 50S ribosomal subunitATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on esomeprazole + amoxicillin + clarithromycin + bismuth potassium citrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esomeprazole + amoxicillin + clarithromycin + bismuth potassium citrate.